U.S.-listed shares of GW Pharmaceuticals rose 8 percent as the company’s marijuana-based treatment Epidiolex cleared the last hurdle after the Drug Enforcement Administration labeled the drug as having a low abuse potential.

Zogenix Inc.’s drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer’s shares up as much as 26 percent.

GW Pharmaceuticals’ cannabis-derived medicine for severe childhood epilepsy won a favorable review from the U.S. FDA.